{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:27:31Z","timestamp":1779114451065,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1245\/s10434-025-18880-8","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:23:27Z","timestamp":1765898607000},"page":"3084-3090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcome Analysis of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion (HITHOC) for Pseudomyxoma Peritonei with Pleural Metastasis"],"prefix":"10.1245","volume":"33","author":[{"given":"Edra","family":"Ha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-1625","authenticated-orcid":false,"given":"Yota","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inderpal S.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Crentsil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olugbenga","family":"Okusanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Luketich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Awais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Haroon A.","family":"Choudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil A.","family":"Christie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"18880_CR1","doi-asserted-by":"crossref","unstructured":"Sommariva A, Tonello M, Rigotto G et al. Novel perspectives in pseudomyxoma peritonei treatment. Cancers (Basel) 2021; 13 (23).","DOI":"10.3390\/cancers13235965"},{"key":"18880_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/690256","volume":"2012","author":"T Kitai","year":"2012","unstructured":"Kitai T. Pulmonary metastasis from pseudomyxoma peritonei. Gastroenterol Res Pract. 2012;2012:690256.","journal-title":"Gastroenterol Res Pract"},{"issue":"5","key":"18880_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/02656736.2017.1310938","volume":"33","author":"R Mittal","year":"2017","unstructured":"Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511\u20139.","journal-title":"Int J Hyperthermia"},{"key":"18880_CR4","unstructured":"Vaira M, Cioppa T, G DEM et al. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. In Vivo 2009; 23 (4): 639-644."},{"issue":"3","key":"18880_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363.","journal-title":"JAMA Surg"},{"issue":"5","key":"18880_CR6","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0003-4975(97)00806-0","volume":"64","author":"KD Mortman","year":"1997","unstructured":"Mortman KD, Sugarbaker PA, Shmookler BM, et al. Pulmonary metastases in pseudomyxoma peritonei syndrome. Ann Thorac Surg. 1997;64(5):1434\u20136.","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"18880_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12957-021-02171-z","volume":"19","author":"B Trilling","year":"2021","unstructured":"Trilling B, Brind\u2019Amour A, Hamad R, et al. Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index. World J Surg Oncol. 2021;19(1):60.","journal-title":"World J Surg Oncol"},{"issue":"20","key":"18880_CR8","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449\u201356.","journal-title":"J Clin Oncol"},{"issue":"2","key":"18880_CR9","first-page":"929","volume":"38","author":"M Robella","year":"2018","unstructured":"Robella M, Vaira M, Borsano A, et al. Low-dose pressurized intrathoracic aerosol chemotherapy (PITAC) as an alternative therapy for pleuropulmonary involvement in pseudomyxoma peritonei. Anticancer Res. 2018;38(2):929\u201332.","journal-title":"Anticancer Res"},{"issue":"5","key":"18880_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4240\/wjgs.v10.i5.49","volume":"10","author":"SA Rizvi","year":"2018","unstructured":"Rizvi SA, Syed W, Shergill R. Approach to pseudomyxoma peritonei. World J Gastrointest Surg. 2018;10(5):49\u201356.","journal-title":"World J Gastrointest Surg"},{"key":"18880_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0022-5223(19)33271-4","volume":"49","author":"NR Thomford","year":"1965","unstructured":"Thomford NR, Woolner LB, Clagett OT. The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg. 1965;49:357\u201363.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"18880_CR12","doi-asserted-by":"crossref","unstructured":"Blaj S, Dora D, Lohinai Z et al. Prognostic factors in pseudomyxoma peritonei with emphasis on the predictive role of peritoneal cancer index and tumor markers. Cancers (Basel) 2023; 15 (4).","DOI":"10.3390\/cancers15041326"},{"issue":"30","key":"18880_CR13","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.2217\/fon-2021-0317","volume":"17","author":"M Migliore","year":"2021","unstructured":"Migliore M, Combellack T, Williams J, et al. Hyperthermic intrathoracic chemotherapy in thoracic surgical oncology: future challenges of an exciting procedure. Future Oncol. 2021;17(30):3901\u20134.","journal-title":"Future Oncol"},{"issue":"1","key":"18880_CR14","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/02656736.2022.2104938","volume":"39","author":"V Proesmans","year":"2022","unstructured":"Proesmans V, Vandaele T, Van Slambrouck J, et al. Pleural decortication and hyperthermic intrathoracic chemotherapy for pseudomyxoma. Int J Hyperthermia. 2022;39(1):1153\u20137.","journal-title":"Int J Hyperthermia"},{"issue":"59","key":"18880_CR15","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.18632\/oncotarget.22062","volume":"8","author":"ZY Zhao","year":"2017","unstructured":"Zhao ZY, Zhao SS, Ren M, et al. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget. 2017;8(59):100640\u20137.","journal-title":"Oncotarget"},{"key":"18880_CR16","doi-asserted-by":"crossref","unstructured":"Danuzzo F, Sibilia MC, Vaquer S et al. The role of hyperthermic intrathoracic chemotherapy (HITHOC) in thoracic tumors. Cancers (Basel) 2024; 16 (14).","DOI":"10.3390\/cancers16142513"},{"key":"18880_CR17","doi-asserted-by":"publisher","first-page":"1259779","DOI":"10.3389\/fonc.2023.1259779","volume":"13","author":"M Hassan","year":"2023","unstructured":"Hassan M, Zimmermann J, Schmid S, et al. Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases. Front Oncol. 2023;13:1259779.","journal-title":"Front Oncol"},{"key":"18880_CR18","doi-asserted-by":"crossref","unstructured":"Campany ME, Reck Dos Santos PA, Donato BB et al. Hyperthermic intrapleural chemotherapy: an update. J Thorac Dis 2023; 15 (9): 5064-5073.","DOI":"10.21037\/jtd-23-454"},{"issue":"11","key":"18880_CR19","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.21037\/jtd-23-466","volume":"15","author":"IA Elliott","year":"2023","unstructured":"Elliott IA, He H, Lui NS, et al. Impact of hyperthermic intrathoracic chemotherapy (HITHOC) during resection of pleural mesothelioma on patient survival. J Thorac Dis. 2023;15(11):6140\u201350.","journal-title":"J Thorac Dis"},{"issue":"1","key":"18880_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005532","volume":"96","author":"H Zhou","year":"2017","unstructured":"Zhou H, Wu W, Tang X, et al. Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(1):e5532.","journal-title":"Medicine (Baltimore)"},{"key":"18880_CR21","doi-asserted-by":"crossref","unstructured":"J\u00e4rvinen T, Paajanen J, Ilonen I, R\u00e4s\u00e4nen J. Hyperthermic intrathoracic chemoperfusion for malignant pleural mesothelioma: systematic review and meta-analysis. Cancers (Basel) 2021; 13 (14).","DOI":"10.3390\/cancers13143637"},{"issue":"Suppl 1","key":"18880_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13193-023-01728-6","volume":"14","author":"V Kepenekian","year":"2023","unstructured":"Kepenekian V, Sgarbura O, Marchal F, et al. Peritoneal mesothelioma: systematic review of hyperthermic intraperitoneal chemotherapy (HIPEC) protocol outcomes. Indian J Surg Oncol. 2023;14(Suppl 1):39\u201359.","journal-title":"Indian J Surg Oncol"},{"issue":"2","key":"18880_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/01.sla.0000152015.76731.1f","volume":"241","author":"TJ Miner","year":"2005","unstructured":"Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241(2):300\u20138.","journal-title":"Ann Surg"},{"issue":"1","key":"18880_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12957-023-03232-1","volume":"21","author":"R Yang","year":"2023","unstructured":"Yang R, Fu YB, Li XB, et al. Long-term survival in patients with PMP: a single-institutional retrospective study from China. World J Surg Oncol. 2023;21(1):347.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"18880_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-021-01723-6","volume":"16","author":"YL Lin","year":"2021","unstructured":"Lin YL, Xu DZ, Li XB, et al. Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines. Orphanet J Rare Dis. 2021;16(1):85.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"18880_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18880-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:52Z","timestamp":1773330472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18880-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["18880"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18880-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"James Luketich owns some stock in several medical device companies but does not receive any salaries or board fees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Approval for this study was obtained from the institutional review board of the University of Pittsburgh (STUDY20050076), which waived the requirement for individual patient consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed patient consent\/consent to publication"}},{"value":"The abstract was  presented at\u00a0the 85th Society of Surgical Oncology Annual Meeting, 27\u201329 March 2025, in Tampa, FL, USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentation"}}]}}